| Symbol | SPRO |
|---|---|
| Name | SPERO THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 675 MASSACHUSETTS AVENUE,14TH FLOOR, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 857 242-1600 |
| Fax | — |
| — | |
| Website | https://www.sperotherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001701108 |
| Description | Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The companys product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Additional info from NASDAQ: |
(30% Negative) SPERO THERAPEUTICS, INC. (SPRO) Reports Q3 2026 Financial Results
Read moreSpero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Read moreSpero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Read moreSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read moreSpero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Read moreSpero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Read moreSpero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Read moreSpero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Read moreSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Read moreDeshpande Milind 🟢 acquired 30.0K shares (1 derivative) of Spero Therapeutics, Inc. (SPRO) at $2.15 Transaction Date: Jun 23, 2026 | Filing ID: 283245
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06727136 | A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pi… | Phase1 | Healthy Participants | Completed | 2024-11-20 | 2025-04-22 | ClinicalTrials.gov |
| NCT06059846 | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intrave… | Phase3 | Urinary Tract Infection | Completed | 2023-12-21 | 2025-02-06 | ClinicalTrials.gov |
| NCT05966688 | A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of … | Phase1 | Healthy Volunteers | Completed | 2023-08-04 | 2024-02-04 | ClinicalTrials.gov |
| NCT05955586 | A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Compari… | Phase1 | Healthy Volunteer | Completed | 2023-08-01 | 2024-02-23 | ClinicalTrials.gov |
| NCT05856747 | A Study to Compare Two Bioanalytical Assays for Tebipenem | Phase1 | Healthy Volunteers | Completed | 2023-05-04 | 2023-06-01 | ClinicalTrials.gov |
| NCT05496374 | A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of… | Phase2 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | Completed | 2022-12-14 | 2024-12-02 | ClinicalTrials.gov |
| NCT05296382 | Bioavailability of Tebipenem (SPR994) Crushed Tablet | Phase1 | Relative Bioavailability | Completed | 2022-04-01 | 2022-12-23 | ClinicalTrials.gov |
| NCT04919954 | Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infection… | Phase1 | Diabetes | Completed | 2021-07-01 | 2022-12-23 | ClinicalTrials.gov |
| NCT04865393 | Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Re… | Phase1 | Renal Impairment | Completed | 2021-06-08 | 2021-12-06 | ClinicalTrials.gov |
| NCT04868292 | Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunt… | Phase1 | Healthy Volunteers | Completed | 2021-06-03 | 2021-09-29 | ClinicalTrials.gov |
| NCT04710407 | Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the … | Phase1 | Healthy Volunteers | Completed | 2020-12-07 | 2021-03-10 | ClinicalTrials.gov |
| NCT04553406 | Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment… | Phase2 | Mycobacterium Avium Complex | Terminated | 2020-12-03 | 2021-01-28 | ClinicalTrials.gov |
| NCT04625855 | Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil H… | Phase1 | Healthy Volunteers | Completed | 2020-09-30 | 2020-10-16 | ClinicalTrials.gov |
| NCT04368585 | Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharma… | Phase1 | Healthy Volunteers | Completed | 2020-07-01 | 2020-08-21 | ClinicalTrials.gov |
| NCT04421885 | Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hyd… | Phase1 | Healthy Volunteers | Completed | 2020-06-01 | 2020-07-29 | ClinicalTrials.gov |
| NCT04376554 | Effect of Tebipenem on Normal Human Intestinal Microbiota | Phase1 | Healthy Volunteers | Completed | 2020-02-10 | 2021-04-06 | ClinicalTrials.gov |
| NCT04238195 | A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over St… | Phase1 | TQT Study | Completed | 2020-01-19 | 2020-02-26 | ClinicalTrials.gov |
| NCT04178577 | Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) … | Phase1 | Renal Impairment | Completed | 2019-12-06 | 2020-09-11 | ClinicalTrials.gov |
| NCT03788967 | Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administere… | Phase3 | Complicated Urinary Tract Infection | Completed | 2019-06-03 | 2020-05-27 | ClinicalTrials.gov |
| NCT03792308 | A First in Human Study of the Safety and Tolerability of Single and Multiple Do… | Phase1 | Healthy Volunteers | Completed | 2018-12-18 | 2019-12-23 | ClinicalTrials.gov |
| NCT03796910 | A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy … | Phase1 | Healthy Volunteers | Completed | 2018-12-18 | 2019-09-24 | ClinicalTrials.gov |
| NCT03376529 | Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 | Phase1 | Healthy Volunteers | Completed | 2017-11-10 | 2017-12-20 | ClinicalTrials.gov |
| NCT03395249 | Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 | Phase1 | Healthy Volunteers | Completed | 2017-10-20 | 2018-08-02 | ClinicalTrials.gov |
| NCT03022175 | A First in Human Study of the Safety and Tolerability of Single and Multiple Do… | Phase1 | Healthy Volunteers | Completed | 2016-12-01 | 2017-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| TBPM-PI-HBr | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04710407 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03022175 |
| SPR741 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03022175 |
| Aztreonam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03376529 |
| Piperacillin/tazobactam | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03376529 |
| Ceftazidime | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03376529 |
| SPR741 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03376529 |
| Orapenem® | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03395249 |
| Placebo Oral Tablet | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03395249 |
| SPR994 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03395249 |
| Placebo for MAD | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03796910 |
| SPR720 for MAD | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03796910 |
| Placebo for SAD | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03796910 |
| SPR720 for SAD | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03796910 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03792308 |
| SPR206 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03792308 |
| Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) | Other | Phase PHASE1 | TQT Study | COMPLETED | NCT04238195 |
| Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) | Other | Phase PHASE1 | TQT Study | COMPLETED | NCT04238195 |
| Moxifloxacin 400mg | Other | Phase PHASE1 | TQT Study | COMPLETED | NCT04238195 |
| Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo | Other | Phase PHASE1 | TQT Study | COMPLETED | NCT04238195 |
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04421885 |
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04421885 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04368585 |
| 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04368585 |
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04368585 |
| TBPM-PI-HBr | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04625855 |
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT04178577 |
| amoxicillin-clavulanate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04376554 |
| TBPM-PI-HBr | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04376554 |
| SPR206 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04868292 |
| Open-label Standard of Care | Other | Phase PHASE2 | Mycobacterium Avium Complex | TERMINATED | NCT04553406 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Avium Complex | TERMINATED | NCT04553406 |
| SPR720 | Other | Phase PHASE2 | Mycobacterium Avium Complex | TERMINATED | NCT04553406 |
| Dummy tablets | Other | Phase PHASE3 | Complicated Urinary Tract Infection | COMPLETED | NCT03788967 |
| Dummy Infusion | Other | Phase PHASE3 | Complicated Urinary Tract Infection | COMPLETED | NCT03788967 |
| Ertapenem | Other | Phase PHASE3 | Complicated Urinary Tract Infection | COMPLETED | NCT03788967 |
| TBPM-PI-HBr | Other | Phase PHASE3 | Complicated Urinary Tract Infection | COMPLETED | NCT03788967 |
| Tebipenem Pivoxil Hydrobromide | Other | Phase PHASE1 | Diabetes | COMPLETED | NCT04919954 |
| Tube feeds | Other | Phase PHASE1 | Relative Bioavailability | COMPLETED | NCT05296382 |
| Tebipenem tablet form | Other | Phase PHASE1 | Relative Bioavailability | COMPLETED | NCT05296382 |
| Ethambutol | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05966688 |
| Azithromycin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05966688 |
| SPR720 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05966688 |
| SPR720 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05955586 |
| TBP-PI-HBr | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05856747 |
| SPR206 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT04865393 |
| TBP-PI-HBr | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06727136 |
| SPR720 1000 mg | Other | Phase PHASE2 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | COMPLETED | NCT05496374 |
| SPR720 500 mg | Other | Phase PHASE2 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | COMPLETED | NCT05496374 |
| Placebo | Other | Phase PHASE2 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | COMPLETED | NCT05496374 |
| Dummy Tablets | Other | Phase PHASE3 | Urinary Tract Infection | COMPLETED | NCT06059846 |
| Dummy Infusion | Other | Phase PHASE3 | Urinary Tract Infection | COMPLETED | NCT06059846 |
| Imipenem-cilastatin | Other | Phase PHASE3 | Urinary Tract Infection | COMPLETED | NCT06059846 |
| TBP-PI-HBr | Other | Phase PHASE3 | Urinary Tract Infection | COMPLETED | NCT06059846 |